China Resources Double-Crane Pharmaceutical (600062.SH): Passed GMP compliance inspection.

On December 17, Gelonghui reported that China Resources Double-Crane Pharmaceutical (600062.SH) announced it has received the "Pharmaceutical GMP Compliance Inspection Notification" issued by the Peking Municipal Pharmaceutical Supervision Administration. This is the first pharmaceutical GMP compliance inspection before the market launch of Sugengutong Sodium Injection, conducted on a newly constructed production line based on the existing factory. The investment in the new workshop production equipment and facilities amounts to 12.9496 million yuan (unaudited). The company passing this pharmaceutical GMP compliance inspection indicates that its product production quality management meets GMP requirements, which will be beneficial for the company to continue maintaining stable production.

Gelonghui FinanceDec 17 04:03 ET

CR Double-Crane Pharma's Nine Drugs Chosen in China's Centralized Drug Bid; Shares Down 3%

MT NewswiresDec 15 23:58 ET

China Resources Double-Crane Pharmaceutical (600062.SH) intends to be selected in the national centralized procurement of Pharmaceuticals.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that on December 12, 2024, the company and some of its subsidiaries...

Zhitong FinanceDec 13 05:38 ET

Here's Why China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt Responsibly

Simply Wall StDec 12 21:49 ET

China Resources Double-Crane Subsidiaries Secure Drug Approvals

MT NewswiresNov 28 22:41 ET

China Resources Double-Crane Pharmaceutical (600062.SH): Some products of its subsidiary have obtained pharmaceutical registration certificates.

On November 28, great wisdom announced that its wholly-owned subsidiary china resources double-crane pharmaceutical (600062.SH), its wholly-owned subsidiary Li Min Pharmaceutical Industry (Jinan) Co., Ltd. received the National Medical Products Administration (hereinafter referred to as “NMPA”) issued the registration certificate for Sacubitril Valsartan Tablets, and its wholly-owned subsidiary Anhui Shuanghe Pharmaceuticals Co., Ltd. received the NMPA issued the registration certificate for Sodium Bicarbonate Ringer Injection. Sacubitril Valsartan Tablets are used in adult patients with chronic heart failure with reduced ejection fraction (NYHA II-IV, LVEF ≤ 40%) to reduce cardiovascular death and heart failure.

Gelonghui FinanceNov 28 03:53 ET